American Epilepsy Society Annual Meeting 2018

The American Epilepsy Society's (AES) 72nd Annual Meeting convened on November 30 to December 4, 2018. At the meeting, AES promotes both basic and clinical research at the vanguard of diagnosing, treating, and curing epilepsy offering high-quality educational content across diverse work settings, professional roles, and experience levels.
Despite accessibility to antiepileptic drugs in high-income settings, more than one-third of patients with newly diagnosed epilepsy were not treated or had delayed treatment.
The director of the Pediatric Epilepsy Center at UCSF Benioff Children’s Hospital discussed the efficacy profile of ZX008, for which Zogenix recently submitted a new drug application to the FDA for the treatment of Dravet syndrome.
The neurologist and epileptologist at the Mayo Clinic in Jacksonville spoke about how to best identify adult patients in need of routine EEG and what it will bring to the table relative to the clinician.
The Director of the Pediatric Epilepsy Center at UCSF Benioff Children's Hospital spoke about what defines a "clinically meaningful change in seizure frequency" using data from a phase 3 clinical trial of ZX008 for the adjunctive treatment of seizures associated with Dravet syndrome.
Uliel-Sibony discussed her and her colleagues' study of CBD, and its findings on when tolerance develops for which patient population.
The Clinical Fellow in Neurophysiology and Epilepsy at Massachusetts General Hospital spoke about the implications of this assessment of SUDEP.
The attending neurologist at Brigham and Women's Hospital spoke about how seizure frequency during pregnancy and postpartum varies by epilepsy type.
The Director of the cEEG and Epilepsy Consult Service at the Cleveland Clinic Epilepsy Center spoke about the cautious for physicians treating patients with acute symptomatic seizures. 
The pediatric epileptologist at Nicklaus Children’s Hospital spoke about the long-term seizure freedom data that showed that perampanel was associated with a sustained or increased improvement in seizure control.
The professor of pediatrics at Tel Aviv University explained what has been fleshed out by the research and shared his opinion on cannabidiol’s use.
The head of the Children’s Brain Dynamics Laboratory at Boston Children’s Hospital discussed the HOPE project and its goals moving forward.
The pediatric epileptologist and adjunct professor of pediatrics at the University of Calgary spoke about how drastically things have changed surrounding the patient-physician conversation about SUDEP.
The Director of the Cleveland Clinic Epilepsy Center spoke about how important it is for clinicians to not select the wrong patients for deep brain stimulation. 
The epileptologist at the University of Pennsylvania spoke about the multiple options for patients with epilepsy and the need for a better understanding of choosing from the options.
The director of the epilepsy center at Cleveland Clinic spoke about the process that leads to the selection of candidacy for deep brain stimulation.  
The pediatric psychologist at Children’s Medical Center discussed what her team does to assess patients in the clinic when something comes up as a result of a patient’s screening.
The Director of the Epilepsy Division at Mayo Clinic in Phoenix discussed the issue of driving when withdrawing patients off seizure medication either because of treatment, remission or surgical intervention.
The section chief of pediatric neurology at Nationwide Children’s Hospital discussed cannabidiol's potential in the Lennox-Gastaut syndrome space.
The Director of the Stanford Epilepsy Center discussed the work that’s left to be done in the field of epilepsy.
The instructor in neurology at Beth Israel Deaconess Medical Center spoke about what clinicians can do right now to mitigate the risk of SUDEP and the myriad of options for them to utilize.
The SVP and chief strategy and development officer at Aquestive Therapeutics discussed the hope to provide both patients and providers with a more favorable, and still efficacious, option for seizure clusters.
The Director of the UCLA Seizure Disorder Center explained the importance of referring patients with seizures to epilepsy centers.
The Director of the Stanford Epilepsy Center discussed the current activities of epileptologists and considered how this might change in the near future, given advancing technology.
The associate professor of neurology at the University of Rochester shared some of her advice for treating patients with epilepsy and focusing on the patient.
The section chief of pediatric neurology at Nationwide Children’s Hospital and an associate professor of clinical pediatrics and neurology at The Ohio State University College of Medicine spoke about what the findings mean for patients.